Sinaptica Therapeutics

Sinaptica Therapeutics

Medical Devices, 330 Brookline Ave, Cambridge, Massachusetts, 02215, United States, 1-10 Employees

sinapticatx.com

  • LinkedIn

phone no Phone Number: +16*********

Who is SINAPTICA THERAPEUTICS

Sinaptica TherapeuticsTM is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimers Disease (AD). The company was...

Read More

map
  • 330 Brookline Ave, Cambridge, Massachusetts, 02215, United States Headquarters: 330 Brookline Ave, Cambridge, Massachusetts, 02215, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Billion and Over

industries-icon Industry: Medical Devices

SIC SIC Code: 8011 | NAICS Code: 621111 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from SINAPTICA THERAPEUTICS

Sinaptica Therapeutics Org Chart and Mapping

Employees

Emiliano Santarnecchi

Cofounder and Scientific Advisor

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Sinaptica Therapeutics

Answer: Sinaptica Therapeutics's headquarters are located at 330 Brookline Ave, Cambridge, Massachusetts, 02215, United States

Answer: Sinaptica Therapeutics's phone number is +16*********

Answer: Sinaptica Therapeutics's official website is https://sinapticatx.com

Answer: Sinaptica Therapeutics's revenue is $1 Billion and Over

Answer: Sinaptica Therapeutics's SIC: 8011

Answer: Sinaptica Therapeutics's NAICS: 621111

Answer: Sinaptica Therapeutics has 1-10 employees

Answer: Sinaptica Therapeutics is in Medical Devices

Answer: Sinaptica Therapeutics contact info: Phone number: +16********* Website: https://sinapticatx.com

Answer: Sinaptica TherapeuticsTM is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimers Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The companys SinaptiStimTM System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the company's neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimers patients in over two decades, and is protected by multiple pending patents.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access